PremiumRatingsHold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects Intra-Cellular reports Q4 EPS (16c), consensus (11c) Intra-Cellular downgraded to Hold from Buy at Canaccord PremiumThe FlyRoth MKM biotech analyst holds an analyst/industry conference call Intra-Cellular downgraded to Neutral from Overweight at Piper Sandler Intra-Cellular downgraded to Market Perform from Outperform at Leerink PremiumThe FlyIntra-Cellular downgraded to Neutral from Overweight at Cantor Fitzgerald Intra-Cellular downgraded to Hold from Buy at Needham Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley 
